Van Dijk Backs Half-Dose PDT for Complete Fluid Resolution in CSC
Ophthalmologists evaluated why half-dose photodynamic therapy outperforms other interventions for central serous chorioretinopathy, focusing on the complete elimination of subretinal fluid to prevent lasting retinal damage.
Key Clinical Takeaways:
- Half-dose photodynamic therapy outperforms micropulse laser treatment and eplerenone in resolving chronic central serous chorioretinopathy.
- Eliminating all subretinal fluid is critical, as partial resolution leaves fluid that causes prolonged damage to the outer retina and retinal pigment epithelium.
- Mineralocorticoid receptor antagonists such as eplerenone and spironolactone show no proven clinical benefit compared to placebo in randomized controlled trials.
Fluid Resolution and Retinal Protection in Chronic Cases
In chronic central serous chorioretinopathy, subretinal fluid accumulates beneath the fovea, driven by underlying mechanisms that remain incompletely understood. Clinicians must target complete fluid resolution because even partial clearing allows persistent fluid to cause prolonged damage to the outer retina and retinal pigment epithelium. Because fluid accumulation in this condition naturally waxes and wanes, experts emphasized that only randomized controlled trials can separate a true treatment effect from spontaneous disease fluctuation.
Comparative Trial Outcomes in Chronic Disease
Recent randomized controlled trials have clarified the efficacy hierarchy for chronic central serous chorioretinopathy. The PLACE trial demonstrated that half-dose photodynamic therapy outperformed micropulse laser treatment for both anatomical and visual outcomes in both the short and long term. Similarly, the SPECTRA trial showed half-dose photodynamic therapy to be superior to the mineralocorticoid receptor antagonist eplerenone, marketed as Inspra by Pfizer. In contrast, the UK-based VICI trial found that eplerenone produced results similar to placebo, noting that fluid resolved in 30 percent of the placebo group and in an even lower proportion of patients receiving eplerenone. Based on these accumulated trial data, specialists conclude that eplerenone and spironolactone, marketed as Aldactone by Pfizer, hold no therapeutic role in managing the disease.
Half-Dose Photodynamic Therapy Treats Acute Cases
While no randomized controlled trials have evaluated acute central serous chorioretinopathy, spontaneous resolution occurs more frequently in acute cases. However, certain patients still require active intervention, particularly when rapid visual recovery is necessary. Larger retrospective studies support half-dose photodynamic therapy as the treatment of choice for that specific patient subset. The efficacy of photodynamic therapy stems from its direct effect on choroidal abnormalities, which extend far more widely than abnormalities in the retinal pigment epithelium and subretinal space. Broadly targeting these choroidal pathways is what ultimately achieves a completely dry retina.
Verteporfin Shortages Necessitate Predictive Patient Selection
Future management of central serous chorioretinopathy depends on developing predictive calculations to identify which patients will achieve spontaneous resolution. Such tools would incorporate multimodal imaging, clinical features, and potential genetic profiles to estimate short- and long-term prognosis. Current shortages of verteporfin, marketed as Visudyne by Bausch + Lomb, make careful patient selection increasingly critical. Clinicians face ongoing challenges regarding drug supply and regional reimbursement, making cross-border collegial support essential for securing access to photodynamic therapy equipment and medications.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.